Modulation of contractile function through neuropeptide Y receptors during development of cardiomyocyte hypertrophy

Journal of Pharmacology and Experimental Therapeutics

Volumn 319, Issue 3, 2006, Pages 1286-1296

  Allen, Adrian R ^a   Kelso, Elizabeth J ^a   Bell, David ^a,b   Zhao, YouYou ^a   Dickson, Paula ^a   McDermott, Barbara J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b Whitla Medical Building   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPRENALINE; MESSENGER RNA; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR AGONIST; NEUROPEPTIDE Y RECEPTOR ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; DRUG POTENCY; ELECTROSTIMULATION; HEART CONTRACTION; HEART MUSCLE CELL; HYPERTROPHIC CARDIOMYOPATHY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT;

ANIMALS; ARGININE; CALCIUM; CARDIOTONIC AGENTS; CELL DIFFERENTIATION; CELL SEPARATION; CELL SIZE; ELECTRIC STIMULATION; HYPERTROPHY, LEFT VENTRICULAR; ISOPROTERENOL; MALE; MEMBRANE PROTEINS; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PEPTIDE YY; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTORS, NEUROPEPTIDE Y; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 33751168741     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.110445     Document Type: Article

References (37)

1. Agabiti-Rosei E and Muiesan ML (2001) Hypertensive left ventricular hypertrophy: patho-physiological and clinical issues. Blood Pressure 10:288-298.
2. Allen JM, Gjorstrup P, Bjorkman JA, Ek L, Abrahamsson T, and Bloom SR (1986) Studies on cardiac distribution and function of neuropeptide Y. Acta Physiol Scand 126:405-411.
3. Anversa P, Leri A, and Kajstura J (2006) Cardiac regeneration. J Am Coll Cardiol 47:1769-1776.
4. Aoyagi T, Fujii AM, Flanagan MF, Arnold LW, Brathwaite KW, Colan SD, and Mirsky I (1993) Transition from compensated hypertrophy to intrinsic myocardial dysfunction during development of left ventricular pressure-overload hypertrophy in conscious sheep: systolic dysfunction precedes diastolic dysfunction. Circulation 88:2415-2425.
5. 5 receptor in the spontaneously hypertensive rat. J Pharmacol Exp Ther 303:581-591.
6. Bell D, Lee GR, Kelso EJ, Allen AR, and McDermott BJ (2004) Temporal dependence of the onset of parameters of cardiomyocyte hypertrophy in response to pressure overload in the spontaneously hypertensive rat. Cardiovasc Pathol 13:71-78.
7. i proteins in prehypertensive and hypertensive spontaneously hypertensive rats. J Cardiovasc Pharmacol 23:980-987.
8. Bohm M, Grabel C, Knorr A, and Erdmann E (1994) Treatment in hypertensive cardiac hypertrophy 1: NPY and beta-adrenoceptors. Hypertension 25:954-961.
9. Cerbai E, Barbieri M, Li Q, and Mugelli A (1994) Ionic basis of action potential prolongation of hypertrophied cardiac myocytes from hypertensive rats of different ages. Cardiovasc Res 28:1180-11087.
10. Chen SH and Han QD (1995) Increase of release of NPY in vitro from platelets of spontaneously hypertensive rats. Acta Pharmacol Sin 16:149-151.
11. Doods H, Gaida W, Wieland HA, Dollinger H, Schnorrenberg G, Esser F, Engel W, Eberlein W, and Rudolf K (1999) BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist. Eur J Pharmacol 384:R3-R5.
12. 1 receptor antagonist: a review of its pharmacological properties. Regul Peptides 65:71-77.
13. Franco-Cereceda A, Lundberg JM, and Dahlof C (1985) Neuropeptide Y and sympathetic control of heart contractility and coronary vascular tone. Acta Physiol Scand 124:361-369.
14. Grandt D, Schimiczek M, Rascher W, Feth F, Shively J, Lee TD, Davis MT, Reeve JRJ, and Michel MC (1996) Neuropeptide Y 3-36 is an endogenous ligand selective for Y2 receptors. Regul Peptides 67:33-37.
15. Hanna MK and Khairallah PA (1986) Alterations of myocardial alpha-1 adrenergic receptors in hypertensive cardiac hypertrophy of the rat. Arch Int Pharmacodyn Ther 283:80-93.
16. Heredia M del P, Delgado C, Pereira L, Perrier R, Richard S, Vassort G, Benitah J-P and Gomez AM (2005) Neuropeptide Y rapidly enhances calcium transients and calcium sparks in adult rat ventricular myocytes through Y receptor and PLC activation. J Mol Cell Cardiol 38:205-212.
17. Hu Y, Bloomquist BT, Cornfield LJ, DeCarr LB, Flores-Riveros JR, Friedman L, Jiang P, Lewis-Higgins L, Sadlowski Y, Schaefer J, et al. (1996) Identification of a novel hypothalamic neuropeptide Y receptor associated with feeding behavior. J Biol Chem 271:26315-26319.
18. Hulting J, Sollevi A, Ullman B, Franco-Cereceda A, and Lundberg JM (1990) Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. Cardiovasc Res 24:102-108.
19. 2+ in heart and vascular smooth muscle cells. Can J Physiol Pharmacol 78:162-172.
20. Kassis S, Olasmaa M, Terenius L, and Fishman PH (1987) Neuropeptide Y inhibits cardiac adenylate cyclase through a pertussis toxin-sensitive G-protein. J Biol Chem 262:3429-3431.
21. 3 in SHR cells. Mol Cell Biochem 119:51-57.
22. Kawaguchi H, Shoki M, Sano H, Kudo T, Sawa H, Mochizuki N, Okamato H, Endo Y, and Kitabatake A (1992) PI metabolism in hypertrophied rat heart. J Mol Cell Cardiol 24:1003-1010.
23. Kelso E, McDermott B, Silke B, and Spiers JP (2000) Positive effect of bumetanide on contractile activity of ventricular cardiomyocytes. Eur J Pharmacol 400:43-50.
24. Maisel AS, Scott NA, Motulsky HJ, Michel MC, Boublik JH, Rivier JE, Ziegler M, Allen RS, and Brown MR (1989) Elevation of plasma neuropeptide Y levels in congestive heart failure. Am J Med 86:43-48.
25. 2 subtypes of neuropeptide Y receptors linked to opposing postjunctional effects observed in rat cardiac myocytes. Eur J Pharmacol 336:257-265.
26. Millar BC, Piper HM, and McDermott BJ (1988) The antiadrenergic effect of neuropeptide Y on the ventricular cardiomyocyte. N- S Arch Pharmacol 338:426-429.
27. Millar BC, Weis T, Piper HM, Weber M, Borchard U, McDermott BJ, and Balasubramaniam A (1991) Positive and negative contraction effects of neuropeptide Y on ventricular cardiomyocytes. Am J Physiol 261:H1727-H1733.
28. Ogawa T, Kitamura K, Kawamoto M, Eto T, and Tanaka K (1989) Increased immunoreactive neuropeptide Y in platelets of spontaneously hypertensive rats (SHR). Biochem Biophys Res Commun 165:1399-1405.
29. Ogawa T, Kitamura K, Kangawa K, Matsuo H, and Eto T (1992) Platelet NPY in spontaneously hypertensive rats. J Hypertension 10:765-771.
30. Okamoto K and Aoki K (1963) Development of a strain of spontaneously hypertensive rats. Jpn Circ J 27:282-293.
31. Onuoha GN, Nicholls DP, Alpar EK, Ritchie A, Shaw C, and Buchanan K (1999) Regulatory peptides in the heart and major vessels of man and mammals. Neuropeptides 33:165-172.
32. Pfeffer MA, Pfeffer JM, and Frohlich D (1976) Pumping ability of the hypertrophying left ventricle of the spontaneously hypertensive rat. Circ Res 38:423-429.
33. Piper HM, Millar BC, and McDermott BJ (1989) The negative inotropic effect of neuropeptide Y on the ventricular cardiomyocyte. Naunyn-Schmiedeberg's Arch Pharmacol 340:333-337.
34. Xiao YF and McArdle JJ (1994) Elevated density and altered pharmacologic properties of myocardial calcium current of the spontaneously hypertensive rat. J Hypertension 12:783-790.
35. Yokoshiki H, Kohya T, Tomita F, Tohse N, Nakaya H, Kanno M, and Kitabatake A (1997) Restoration of action potential duration and transient outward current by regression of left ventricular hypertrophy. J Mol Cell Cardiol 29:1331-1339.
36. Zhao YY, Bell D, Smith LR, Zhao L, Devine AB, McHenry EM, Nicholls DP, and McDermott BJ (2006) Differential effects of components of the cardiomyocyte adrenomedullin/intermedin receptor system following blood pressure reduction in nitric oxide-deficient hypertension. J Pharmacol Exp Ther 316:1269-1281.
37. Zukowskagrojec ZG, Olczyska M, Shen GH, Torresduarte A, Haass M, Wahlestedt C, and Myers AK (1993) Modulation of vascular function by neuropeptide Y during development of hypertension in spontaneously hypertensive rats. Pediatr Nephrol 7:845-852.